• Precigen swung to net income of $35.8 million in the third quarter of 2026 from a year-earlier loss.
• Total revenue rose year-over-year to $74.1 million, primarily driven by PAPZIMEOS commercial sales.
• PAPZIMEOS revenue climbed 37% quarter-over-quarter to $72.9 million.
• Operating cash flow reached positive $11.9 million, achieving positive cash flow a quarter ahead of guidance.
• The FDA granted AdenoVerse Platform Technology Designation, creating opportunities to expedite development of current and future therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611041605PR_NEWS_USPR_____NY88425) on November 04, 2026, and is solely responsible for the information contained therein.